logo
  

GSK : Preclinical Data Show Sotrovimab Retains Activity Against Omicron Mutations

GlaxoSmithKline plc. (GSK,GSK.L) and Vir Biotechnology Inc. (VIR) said preclinical data demonstrated that sotrovimab, an investigational monoclonal antibody, retains activity against key mutationsof the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.

The companies said that the data will be confirmed by further in vitro pseudo-virus testing. They plans to provide an update on it by the end of 2021.

GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection. Insurance company Prudential plc reported Wednesday a sharp drop in first-half pre-tax profit. On an after-tax basis, the company recorded a profit, compared to last year's hefty loss, due to the absence of prior year's loss from discontinued operations. Separately, Prudential announced its 2022 first interim dividend of 5.74 US cents per ordinary share, which will be paid on September 27.
Follow RTT